ANNUAL REPORT 2026 9 Nepean Hospital in New South Wales was activated during the year, followed shortly after year-end by Sir Charles Gairdner Hospital in Western Australia. Recruitment is underway, with the first patient dosed shortly after the financial year closed. The trial remains on track to complete in CY2027, with final patient dosing expected in mid-2027 and top-line results anticipated approximately three months after the last patient completes their 30-day follow-up assessment. Broadening the Pipeline During the year, we deliberately extended the Xolatryp program into oncology, an area where our TRPC mechanism has compelling scientific rationale. In the first of two preclinical studies, Xolatryp demonstrated clear anti-tumour activity in a liver cancer model, both as a monotherapy and in combination with doxorubicin. The combination produced the greatest reduction in tumour volume and was well tolerated. The second, a pilot study, was conducted ahead of a larger cardiomyopathy study, designed to assess whether Xolatryp can protect the heart in patients receiving doxorubicin. This pilot study confirmed the feasibility and tolerability of the intended subcutaneous dosing regimen, informing dose selection for the larger study to come. The dosing phase of the larger study has now been completed with the results data currently being compiled and analysed. “The past year saw Nyrada become a company that doses patients, protects its inventions across key markets, and pursues its science on more than one front.” Regulatory Progress To support entry into the United States, we have begun preparing an Investigational New Drug (IND) application for submission to the FDA for our myocardial ischemia-reperfusion injury program. We plan to submit the application before the end of the 2026 calendar year, establishing a clear regulatory pathway into the world’s largest healthcare market. Intellectual Property Protecting Xolatryp remained a priority throughout the year. Our composition of matter patent application was published, our Xolatryp® trademark was granted, and the Company received a Notice of Allowance from the US Patent Office late in the financial year. Subject to payment of the issue fee, the granted patent will secure protection over Xolatryp's chemical structure in the United States for a twenty-year term from the September 2024 filing date. Financial Summary Throughout FY2026, Nyrada continued to maintain disciplined capital and cost management while ensuring its clinical and research programs were fully funded. The year opened on the strength of the AU$8.25 million (before costs) placement completed shortly after the FY2025 year-end. The funds raised were to be directed toward the Phase IIa trial, drug manufacture, and further preclinical research. During the year the Company received an R&D tax rebate of AU$2.45 million in respect of its FY2025 claim. A further $2.29 million was received during the year from the exercise of options. As at 30 June 2026, the Company's cash position was $8.38 million. A full accounting of the Company's financial performance and position appears in the Directors' Report and financial statements that follow.
RkJQdWJsaXNoZXIy MjE2NDg3